MicroVue™ BAP EIA

The MicroVue BAP EIA provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum.


Product Specifications

Citations 21
Specimen

Serum 20 μL

LLOQ 2 U/L
ULOQ 140 U/L
Assay Time 3.5 hours
Cross Reactivity

Baboon, Cow, Cynomolgous monkey, Dog, Goat, Horse, Rabbit, Rat, Rhesus monkey, Sheep

Ordering Information

For In Vitro Diagnostic Use.
Catalog Number 8012
Catalog Number (CE)  
Size 96 wells/test
Price (USD) $970.00
Price (EURO) 680,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue BAP EIA provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum.

Size 96 wells/test
Form

96 well plate with 12 eight-well strips in a resealable foil pouch

Specimen Serum 20 μL
Limit of Detection (LOD) 0.7 U/L
Lower Limit of Quantitation (LLOQ) 2 U/L
Upper Limit of Quantitation (ULOQ) 140 U/L
Intra Assay 3.9–5.8%
Inter Assay 5.0–7.6%
Standards 6
Controls 2
Sample Values

Females (Ages 25–44) 11.6–29.6 U/L, Males (Ages ≥25) 15.0–41.3 U/L

Assay Time 3.5 hours
Cross Reactivity

Baboon, Cow, Cynomolgous monkey, Dog, Goat, Horse, Rabbit, Rat, Rhesus monkey, Sheep

Storage

Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components

Background

BAP is an enzyme produced by osteoblasts, the cells responsible for bone formation. The MicroVue BAP immunoassay provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in serum as an indicator of osteoblastic activity. Measurement of BAP is intended for use as an aid in the 1) management of postmenopausal osteoporosis and Paget's disease, 2) monitoring of postmenopausal women on hormonal or bisphosphonate therapy, and 3) prediction of skeletal response to hormonal therapy in postmenopausal women.

Citations

Title Year Applications Sample Species Sample Sample Details

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.

2018

ELISA

Cynomolgus Monkey

Serum

Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women.

2010

ELISA

Human

Serum

Calcium requirements and metabolism in Chinese-American boys and girls.

2010

ELISA

Human

Serum

Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: a cross-sectional study.

2013

ELISA

Human

Plasma

Women Using Hormonal Contraceptives

Age-related bone turnover markers and osteoporotic risk in native Chinese women.

2014

ELISA

Human

Serum

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

2014

ELISA

Human

Serum

Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.

2014

ELISA

Human

Serum

Mucopolysaccharidosis Types I, II, and VI in children

Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial.

2014

ELISA

Human

Serum

Cholecalciferol

Ethnic differences in urinary calcium and phosphate excretion between Gambian and British older adults

2015

ELISA

Human

Plasma

Different health behaviours and clinical factors associated with bone mineral density and bone turnover in premenopausal women with and without type 1 diabetes.

2015

ELISA

Human

Serum

Premenopausal Women w/wo Type 1 Diabetes

Higher daily physical activity is associated with higher osteocalcin levels in adolescents.

2015

ELISA

Human

Serum

Obesity, children

Effects of an 8-Month Ashtanga-Based Yoga Intervention on Bone Metabolism in Middle-Aged Premenopausal Women: A Randomized Controlled Study.

2015

ELISA

Human

Serum

Middle-Aged Premenopausal Women

Relationship of serum GDF11 levels with bone mineral density and bone turnover markers in postmenopausal Chinese women.

2016

ELISA

Human

Serum

Postmenopausal women

Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis.

2017

ELISA

Human

Serum

Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers.

2019

ELISA

Human

Serum

Chronic Kidney Disease

Selected serum microRNA, abdominal aortic calcification and risk of osteoporotic fracture.

2019

ELISA

Human

Serum

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

2018

ELISA

Human

Serum

Low-Salt' Bread as an Important Component of a Pragmatic Reduced-Salt Diet for Lowering Blood Pressure in Adults with Elevated Blood Pressure

2019

ELISA

Human

Serum

Vitamin D and Abdominal Aortic Calcification in Older African American Women, the PODA Clinical Trial.

2020

ELISA

Human

Serum

Older African American Women

The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD – the exploratory randomized controlled double-blind ExplorIRON-CKD study

2024

ELISA

Human

Serum

CKD

Effects of combined maternal administration with alpha-ketoglutarate (AKG) and β-hydroxy-β-methylbutyrate (HMB) on prenatal programming of skeletal properties in the offspring.

2012

ELISA

Porcine

Serum